Jun. 10 at 8:37 PM
$CRVO Well that was a kick in the teeth. If my math is correct, and all of the warrants get exercised, my ownership % has gone down by over half. I'm glad they only used dilutive financing for
$10M -
$30M of their needed runway. It feels as if they must have received feedback that they have to put more skin in the game as a show of confidence before BP would partner with them.
Looking forward, stroke and aphasia trial data need to be strong to ensure the market for neflamipmod is expanding - this is because any funding CRVO receives in a partnership would limit CRVO's direct access to that market segment. I'm not as convinced about the ALS physiologic path to improving patient outcomes as I am the other two, but that could also be a game changer. And, of course, the lengthy DLB phase 3 is the potential home run.
Drug discovery takes time. Buying more at these prices.
